For the Quarter Ending September 2025
North America
• In United States, the Lorazepam Price Index rose quarter-over-quarter in Q3 2025, driven by increasing production costs and shrinking inventories.
• Rising CPI (3.0% in September 2025) indicated higher operational costs for Lorazepam manufacturers.
• Producer Price Index (2.6% in August 2025) increased raw material costs for Lorazepam production.
• US natural gas prices saw an uptick in Q3 2025, increasing Lorazepam production expenses.
• Chemical manufacturers reported shrinking inventories in Q3 2025 due to accelerating destocking, impacting Lorazepam supply.
• US pharmaceutical exports increased in August 2025, while imports decreased, influencing Lorazepam trade flows.
• Strong retail sales (5.42% in September 2025) supported consumer ability to afford Lorazepam healthcare expenses.
• The low unemployment rate (4.3% in September 2025) enhanced consumer disposable income for Lorazepam access.
• Declining consumer confidence in September 2025 suggested potential constraints on Lorazepam consumer spending.
• Chemical manufacturing economic conditions sentiment deteriorated further during Q3 2025.
Why did the price of Lorazepam change in September 2025 in North America?
• Increased raw material costs, evidenced by the 2.6% PPI rise in August 2025, pressured Lorazepam prices upward.
• Higher operational expenses, indicated by the 3.0% CPI increase in September 2025, contributed to rising Lorazepam costs.
• Shrinking chemical inventories in Q3 2025, coupled with natural gas price upticks, tightened Lorazepam supply.
APAC
• In China, the Lorazepam Price Index fell quarter-over-quarter, influenced by significant production cost reductions.
• Lorazepam production costs decreased in Q3 2025, driven by a -2.3% PPI year-on-year in September 2025.
• Demand for Lorazepam was supported by a 3.0% rise in retail sales year-on-year in September 2025.
• The Lorazepam demand outlook remained robust due to China's aging population and rising chronic diseases.
• China's Manufacturing Index contracted in September 2025, indirectly impacting the broader Lorazepam market.
• Industrial production increased by 6.5% year-on-year in September 2025, supporting healthcare spending.
• Trade flows faced challenges from US tariffs effective August 2025, impacting Lorazepam exports.
• Feedstock costs, including 1,4-Butanediol, weakened in July 2025, contributing to lower production expenses.
• Lower electricity prices in China in 2025 provided a cost advantage for Lorazepam manufacturers.
Why did the price of Lorazepam change in September 2025 in APAC?
• Production costs for Lorazepam decreased due to a -2.3% PPI year-on-year in September 2025.
• Deflationary pressures from a -0.3% CPI year-on-year in September 2025 impacted pharmaceutical pricing.
• Weakening 1,4-Butanediol costs in July 2025 contributed to overall lower Lorazepam production expenses.
Europe
• In Germany, Lorazepam Price Index fell in Q3 2025, influenced by suppressed feedstock and mixed demand.
• Lorazepam production costs faced downward pressure in Q3 2025, as PPI declined 1.7% in September.
• Rising CPI (2.4% in September 2025) signaled higher operational costs for Lorazepam producers.
• Demand for Lorazepam was moderately supported in Q3 2025 by pharmaceutical market growth and aging.
• Manufacturing Index contracted in September 2025, Industrial Production declining 1.0%, impacting supply.
• Benzene and Toluene feedstock costs remained suppressed in Q3 2025 due to persistent oversupply.
• Elevated natural gas and electricity prices in Europe pressured Lorazepam production costs.
• Consumer confidence deteriorated to -23.6 in September 2025, potentially impacting healthcare spending.
• Low unemployment (3.9%) in September 2025 supported consumer affordability for prescription medications.
• Retail sales grew 0.8% in September 2025, indicating slight consumer spending resilience.
Why did the price of Lorazepam change in September 2025 in Europe?
• Producer Price Index declined 1.7% in September 2025, reducing Lorazepam input costs in Europe.
• Benzene and Toluene feedstock costs remained suppressed in Q3 2025 due to oversupply, lowering production.
• Elevated natural gas and electricity prices in Q3 2025 increased operational costs for Lorazepam producers.
For the Quarter Ending December 2022
North America
The prices of Lorazepam in the United States mimic similar market sentiments as that of India. Until November, the prices inclined moderately on the back of consistent end-user demand from the domestic market balanced with the overall supplies among the market participants.
However, as the year ended, the prices for Lorazepam dropped gradually in December 2022, which resulted in the stockpiling of inventories among the market players, propelling them to reduce their prices to destock their stockpiles and maintain their profit. Additionally, a decrease in shipping costs, slower consumer demand, and a temporary shutdown of the domestic market kept the price trend of Lorazepam on the weaker side.
APAC
Lorazepam prices witnessed a descending trend throughout the fourth quarter of 2022 in the Asia Pacific region. The prices inclined stably until November and dropped considerably following the last month of the fourth quarter. A slight increase in demand balanced with the stockpiled inventories among the market players kept the prices of Lorazepam on the sturdy side. Rising energy prices additionally impacted the market sentiments of all the sectors, including Pharmaceutical as manufacturing cost and the values of upstream material inclined until the mid of the final quarter of 2022. Later in December, the prices for Lorazepam dropped owing to bearish demand, which resulted in the overall storage of inventories. Overall, the price of Lorazepam noted at the end of the fourth quarter was assembled at USD 790141.93/MT Ex Ahmedabad in India.
Europe
During the fourth quarter of 2022, the European market for Lorazepam also followed a similar pattern to that of Asia Pacific. The market trend primarily began on a healthy note until November in Germany because of increased end-user demand from the pharmaceutical industry. Inquiries from the downstream sector for Lorazepam began to decrease significantly after November, i.e., with the start of December 2022, with enough supplies among the market participants. In addition to that, traders further cut back their placed orders to prevent further stockpiling.
For the Quarter Ending September 2022
North America
The prices of Lorazepam commenced on a higher note in the North American region during the H1 of Q3, with healthy demand witnessed from the downstream sector, then followed the declining trajectory from the mid-half of q3 till the end of September, which was supported by the sufficient supplies with the domestic merchants. Furthermore, halted trading momentum from the exporting countries leading to accumulated cargoes at the ports, assisted the market sentiments of Lorazepam in the USA. Overall, the pricing trends displayed towards the end of q3 were assessed at USD 850/MT CFR Los Angeles in the United States.
APAC
In the APAC region, the price of Lorazepam showcases a decremented trend during the third quarter of 2022. In the first half of q3, the prices went significantly higher, causing a shortage of stocks with the suppliers, which propelled them to increase their quotations. Also, disrupted trading activities leading to delayed shipments and halted manufacturing processes were another factor that supported the market sentiments of Lorazepam in the region. Furthermore, towards the termination of q3, the prices decreased considerably, backed by weaker demand and stockpiled supplies with the settlement of INR65200000/MT Ex Ahmedabad in India.
Europe
In the European region, the prices of Lorazepam mimic a similar trend as in North America, backed by healthy downstream demand in the market. Additionally, due to consistent offtakes from the domestic market amid rising input costs, the prices of Lorazepam inclined significantly. Moreover, delayed exports from China due to Covid restrictions on transportation led to low inventories in the regional market till the end of h1. Following the start of mid-q3 to the end of q3, the prices for Lorazepam dropped down considerably owing to lessening demand with sufficient supplies in the region. The prices witnessed in September for Lorazepam settled at USD 872/MT CFR Hamburg in Germany.
For the Quarter Ending June 2022
North America
In the North American region, the price of Lorazepam decreased during the beginning of the Second Quarter, backed by the increased downstream Lorazepam demand from various end-user industries, including pharmaceutical and biopharmaceuticals. Further, towards the mid of the second half of Q1, the Prices went high, leading to Insufficient supply with higher demand for API. The continuous solid demand from the industries and the heightened crude oil prices admits Russian-Ukraine Geopolitical tension were other factors that resulted in the price increment of Lorazepam. Also, the prices surge owing to the port congestion, leading to higher freight charges. With the end of the Second Quarter, the costs were further reduced in the market, leading to the traders' constant availability and sufficient stock.
Asia Pacific
In the Asia Pacific region, the prices of Lorazepam witnessed a mixed sentiment in the market during the second Quarter of 2022, backed by the decreased downstream demand for Lorazepam API from various pharmaceutical and biopharmaceutical industries. Towards the mid of the second quarter, the prices for Lorazepam API went high suddenly due to increased demand, leading to the shortage of supply from the regional market. Moreover, the supply disruption caused by geopolitical tension between Russia-Ukraine led to augmenting Upstream Crude oil prices and influenced the prices of Lorazepam. The Market of India Lorazepam settled at INR 65000000/MT Ex-Ahmedabad in the month ending the Q2.
Europe
The Lorazepam API market witnessed a seesaw trend in the European market during Q2 of 2022. At the onset of Q2, the prices went down owing to reduced demand from Downstream Pharmaceutical & biopharmaceutical industries. Further, with the starting of May, the cost of Lorazepam soured up due to its increased demand and limited supplies, followed by a halt in the export activities from India, one of the major exporters of Lorazepam to the European region, majorly Germany. In addition to that supply chain disruption, labour shortage was another factor that affected the API market, causing its price to Hike in the European region.
